This article is sponsored content brought to you by Elanco.
While osteoarthritis (OA) in dogs is largely considered a problem for seniors or certain breeds, the truth is that it affects dogs of all ages and sizes. It is our duty to convince pet parents of two things – that OA can strike anyone’s dog, but it can also be managed effectively.
Galliprant™ is a non-COX inhibiting NSAID that’s been making waves overseas as a top-tier choice for the treatment of pain and inflammation associated with OA in dogs. This globally recognised, award-winning medication has effectively treated hundreds of thousands of dogs afflicted with this debilitating condition and has already become a trusted name in the Australian market.
OA doesn’t discriminate
In humans, OA is usually associated with elderly populations, but this is unfortunately not the case when it comes to dogs. Just over a fifth of OA cases occur in dogs aged one year or under1. And when you consider that nearly 75% of dogs are in the moderate to severe stages of OA before they get help2, diagnosing & managing osteoarthritis in young dogs is crucial. While certain breeds like Golden Retrievers, Labradors, Rottweilers, and brachycephalic breeds of dogs may be more predisposed to developing OA, it can affect anyone’s pet – so early detection is vital.
A targeted approach to long-term OA pain management
Appropriate long-term pain management for OA is critical in improving a dog’s quality of life. Much like diabetics don’t stop taking insulin when they feel better, it’s not wise to stop a dog’s OA treatment as soon as their symptoms improve.
Galliprant’s unique mode of action makes it an excellent choice for the long-term treatment of canine OA pain and inflammation. Galliprant’s targeted approach means that it allows the production of prostaglandins involved in important housekeeping functions, such as GIT and renal homeostasis. So Galliprant can be administered for as long as necessary, and treatment adjusted according to a dog’s changing needs.
“Osteoarthritis (OA) is one of the leading chronic morbidities in dogs and can affect patients of all ages. There is no cure for osteoarthritis and management centres around control of pain, improving mobility and minimising disease progression. This is accomplished through diet and weight management, targeted nutritional supplementation, rehabilitation therapy by a qualified professional, and judicious use of appropriate pharmaceuticals. Galliprant is one such pharmaceutical, that represents a new age of targeted therapy for managing conditions such as OA. I have found it particularly useful in young patients with conditions such as hip and elbow dysplasia where it is often the first medication I will try for patients requiring longer term management.”
Dr. Stephen Fearnside BVSc (Hons) FANZCVS (Surgery) DACVSMR MANZCVS (VSMR)
Specialist in Small Animal Surgery
The treatment you can trust
If you’ve been struggling to talk to dog owners about effective and safe long-term OA treatment, put them at ease with the facts. Galliprant has an impressive safety profile3, proven treatment success4, and has already given so many dogs a new lease on life.
1. Mele D. Epidemiology of osteoarthritis. Vet Focus. 2007; 17(3): 4-10.
2. Elanco Market Research VET QUANT DATA Global U&A Target Identification 2016.
3. Rausch-Derra L, et al. Am J Vet Res. 2015; 769(10):853-859.
4. Rausch-Derra L, et al. J Vet Intern Med. 2016; 30:756-763.
Read product leaflet for full instructions. The following mild and generally transient adverse reactions have been observed in dogs treated with grapiprant: vomiting, diarrhoea, inappetance and lethargy. For long-term treatment, appropriate monitoring is recommended.
Galliprant and Elanco diagonal bar logo are trademarks of Elanco. ©2022 Elanco. PM-AU-22-0336.